Notably, vimentin is increased in metastases and circulating tumour cells relative to primary well-differentiated tumours, suggesting that exploring the mechanistic interplay with the endosome-lysosome system could reveal selective therapeutic targets [91,93,94]. This evidence concerns the gene VIM and neoplasm.